Central nervous system (CNS) bleeding is one of the most severe and debilitating manifestations occurring in patients with rare bleeding disorders (RBDs). The aim of this study was to retrospectively collect data on patients affected with RBDs who had CNS bleeding, to establish incidence of recurrence, death rate, neurological sequences, most frequent location, type of bleeding and efficacy of treatments. Results pertained to 36 CNS bleeding episodes in 24 patients with severe deficiency except one with moderate factor VII (FVII) deficiency. Six patients (25%) experienced a recurrence and two had more than one recurrence. Seven patients (29%) had an early onset of CNS bleeding before the first 2 years of life, others (71%) later in life. In 76% of cases, CNS bleeding was spontaneous. CNS bleeding was intracerebral in 19 cases (53%), extracerebral in 10 (28%) and both intracerebral and extracerebral in two cases (6%). Neurosurgery was performed in 11 cases, in association with replacement therapy in seven cases. Seizures were noted in four patients. Residual psychomotor abnormalities were seen in two patients. No death was recorded. To prevent recurrence, 17/24 patients (71%) were put on secondary prophylaxis. In conclusion, recurrence of CNS bleeding was confirmed to be relatively frequent in patients with severe FV, FX, FVII and FXIII deficiencies. Most patients were managed with replacement therapy alone, surgery being reserved for those with worsening neurological conditions. Our results indicate that some RBDs require early prophylactic treatment to prevent CNS bleeding. Optimal dosage and frequency of treatment need further evaluation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2516.2011.02545.x | DOI Listing |
CNS Neurosci Ther
March 2025
Department of Neurology, First Affiliated Hospital of Wenzhou Medical University, Shanghai, China.
Background And Purpose: Current guidelines for acute ischemic stroke (AIS) treatment recommend a lenient upper blood pressure (BP) threshold of 185/110 mmHg. However, stricter BP control has been reported to improve prognosis. This study aims to identify the optimal BP range following thrombolysis.
View Article and Find Full Text PDFTransl Stroke Res
March 2025
Department of Neurosurgery, Guizhou Provincial Peopl's Hospital, Guiyang, China.
The blood-brain barrier (BBB) is a selectively permeable membrane that plays a crucial role in protecting the brain from harmful substances. Its disruption is associated with various central nervous system (CNS) disorders, including hemorrhagic stroke. Evans Blue (EB) dye, a protein-binding tracer, is commonly used to assess BBB permeability.
View Article and Find Full Text PDFCureus
January 2025
Department of Radiology, Osaka Red Cross Hospital, Osaka, JPN.
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS). The coexistence of NMOSD and other autoimmune diseases is well recognized. Additionally, rare cases of NMOSD complicated by posterior reversible encephalopathy syndrome (PRES) have been reported.
View Article and Find Full Text PDFCurr Neuropharmacol
February 2025
Doctor of Excellence Program (DEP), The First Hospital of Jilin University, Xinmin Street No. 1, Changchun, Jilin Province 130021, China.
Microglia are resident immune cells in the brain that have been widely studied for their immune surveillance and phagocytosis. In recent years, the important role of microglia in synapse formation, elimination, and plasticity is gradually being recognized. Synapses are the main communication mode between neurons.
View Article and Find Full Text PDFCNS Neurosci Ther
February 2025
Department of Critical Care Medicine, HuaShan Hospital, Fudan University, Shanghai, China.
Background: Our previous studies demonstrated that CCL17 and its receptor CCR4 play crucial roles in neuroinflammation and microglial activation following intracerebral hemorrhage (ICH). However, the specific mechanisms by which the CCL17/CCR4 axis regulates microglial polarization and hematoma clearance remain unclear.
Aims: This study investigates how the CCL17/CCR4 signaling pathway modulates microglial phenotype transition and enhances hematoma resolution after ICH, building upon our earlier findings showing CCR4's involvement in neuroinflammatory responses.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!